BeOne Medicines AG (ONC)

Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Switzerland
Exchange: NASDAQ
Market cap: $302.50B
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Latest financial period: September 30, 2026
Filed with the SEC: November 5, 2026
Estimated earnings date: Not available
Profit #627 of 1422 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROE/ROA | 56.7% | 41.7% | 30.7% | 20.3% |
Growth #81 of 1422 companies
Payout #1089 of 1422 companies
Safety #527 of 1422 companies
Price #1267 of 1422 companies